New drug combo trial offers hope for tough stomach tumors
NCT ID NCT01991379
Summary
This study is testing whether adding a new drug called MEK162 to the standard treatment (imatinib) works better for people with advanced gastrointestinal stromal tumors (GIST). The research first finds the safest dose, then checks if the combination helps shrink tumors and delays cancer growth. It involves about 75 adults who have not yet received treatment for their advanced GIST.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR (GIST) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.